相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases
Hiroshi Fujiwara et al.
Modern Rheumatology (2014)
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab
Ryo Hiroshima et al.
Modern Rheumatology (2014)
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
Yusuf Yazici et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Tocilizumab: a novel therapy for patients with large-vessel vasculitis
Carlo Salvarani et al.
RHEUMATOLOGY (2012)
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
Henrik Christian Leffers et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis
C. Schmitt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
Taras Gout et al.
CLINICAL RHEUMATOLOGY (2011)
Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study
Tsutomu Takeuchi et al.
RHEUMATOLOGY (2011)
Tocilizumab in Refractory Adult Still's Disease
Xavier Puechal et al.
ARTHRITIS CARE & RESEARCH (2011)
Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis
Xiaoping Zhang et al.
Expert Review of Clinical Pharmacology (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Total cholesterol and LDL levels decrease before rheumatoid arthritis
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
S. L. Gorter et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Cecile Gaujoux-Viala et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
J. L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Tocilizumab in Systemic Lupus Erythematosus Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study
Gabor G. Illei et al.
ARTHRITIS AND RHEUMATISM (2010)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
N. Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab
M. Hirao et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Shumpei Yokota et al.
LANCET (2008)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease
Masashi Matsuyama et al.
INTERNAL MEDICINE (2007)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Interleukin-6: discovery of a pleiotropic cytokine
Tadamitsu Kishimoto
ARTHRITIS RESEARCH & THERAPY (2006)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
M Mihara et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
E Nemeth et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes - Association with a down-regulation of SOX9 expression
F Legendre et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
EHS Choy et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
